The Miller Laboratory is dedicated to understanding neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS) and dementias in order to develop new, effective, and safe treatments.  We focus on translational neuroscience, new therapeutic approaches for neurodegenerative diseases, and precision medicine.

WHAT WE DO

ALS Research

The Miller Lab seeks to understand the pathogenesis of ALS with basic studies focused on SOD1, C9ORF72, TBK-1,  miRNA, protein misfolding, protein kinetics, and genetic modifiers of disease. We employ RNA-targeted therapeutic strategies, mainly using antisense oligonucleotides.

Learn More

Dementia Research

The Miller Lab studies how the various isoforms of the protein tau affect neurodegeneration. We employ RNA-targeted therapeutic strategies using antisense oligonucleotides to develop therapies for dementias involving the tau protein as well as for TREM-2.

Learn More

LATEST NEWS

Experimental Drug Shows Promise for Genetic Form of ALS

American Academy of Neurology Press ReleaseMay 1, 2019
An early stage trial of an investigational therapy for amyotrophic lateral sclerosis (ALS) suggests that people could tolerate the experimental drug and, in exploratory results, the experimental drug was linked to possible slower progression in people with a genetic form of the disease caused by mutations in a gene called superoxide dismutase 1 (SOD1).

HOW YOU CAN HELP

Join our email list
to receive updates from the Miller Lab. 

Sign Up Now

Donate
to help develop new treatments, therapies and cures.

Donate Now